Nve (NVEC) Q4 2026 Earnings Call Transcript

NVE reported a strong quarter with revenue up 45% year over year to $7.65 million and net income up 27% to $4.9 million, or $1.02 per diluted share, covering its $1 quarterly dividend. Full-year revenue rose 2% to $26.3 million, operating cash flow increased 16% to $16.7 million, and margins remained robust despite lower defense sales and contract R&D volatility. Management highlighted completed capacity expansion, new wafer-level chip-scale sensor launches, and a positive outlook for product sales, while warning that tax-credit benefits and capital spending should decline next year.

Analysis

NVEC is transitioning from a “cash-rich niche chip designer” into a capacity-constrained-to-capacity-expanding story, and that changes the earnings elasticity. The new equipment does not just add output; it broadens the feasible product mix into smaller, higher-value wafers, which should raise the share of revenue coming from specialty medical/industrial/robotics sockets where switching costs are highest and qualification cycles are longest. That is a better setup than the headline revenue growth suggests, because it increases the odds of multi-quarter share gains even if broader semiconductor demand only improves modestly.

The near-term market may underappreciate how much of the quarter’s margin strength is structural versus transitory. Tax credits and lower opex helped, but the bigger second-order effect is that the capex cycle is rolling off just as inventory is positioned for demand, so free cash flow should inflect before the income statement fully reflects it. If finished goods can convert without a major working-capital drag, the company can keep paying out cash while still compounding per-share economics; that matters because the dividend mechanically lowers investable cash, making operating cash conversion the key valuation anchor.

The main risk is not demand collapse but mix disappointment: defense and contract R&D remain lumpy, and if nondefense product adoption stalls before the new products scale, the market could penalize the stock for having already priced in a capacity payoff. A more subtle risk is that the tax/credit boost fades next year, creating a difficult comparison just as the company must prove that expansion drove real end-market share gains rather than merely timing-related revenue. The consensus is probably underestimating how durable the medical/robotics design-win pipeline could be, but also overestimating how quickly that converts into reported sales; the stock likely trades on evidence of repeat orders, not first-pass interest.

Key Decisions for Investors

• Long NVEC on pullbacks over the next 2-6 weeks; thesis is that the market is underpricing post-capex operating leverage and design-win conversion, with downside limited by cash generation and dividend support.
• Buy a 3-6 month NVEC call spread rather than stock if liquidity allows; this captures a rerating on evidence of revenue acceleration while capping premium risk if tax benefits fade faster than expected.
• Pair trade: long NVEC / short TXN into the next 1-2 quarters; NVEC has a clearer incremental capacity-driven growth inflection, while TXN is more exposed to broad analog cyclicality and capital intensity.
• If NVEC rallies hard on the headline quarter, trim 25-33% and wait for the first post-tax-credit quarter; that is the more informative test of whether growth is self-sustaining versus credit-assisted.
• Watch for confirmation from distributor/channel commentary and repeat-order cadence in medical/robotics over the next 1-2 quarters; add only if backlog visibility improves, because the stock’s multiple should expand on persistence, not one-off launch enthusiasm.